An Extension Study of the Long-Term Safety, Tolerability, and Efficacy of Tividenofusp Alfa (DNL310) in Participants With Mucopolysaccharidosis Type II (MPS II) From Study DNLI-E-0002 or Study DNLI-E-0007
for Mucopolysaccharidosis II
8 locations incl. Oakland
Sponsor: Denali Therapeutics Inc.
Sex: All·Age: Up to 18
Code: NCT06075537·Phase 2, Phase 3·Enrolling By Invitation